For individuals who are dealing with menstrual cramps, a new OTC topical analgesic, transdermal, pain-relieving cream may help in aiding some discomfort.
Control, which is available through AvKare, is absorbed into the muscles, relaxes the nerves, and works in about one to four minutes, the company said.
Featured ingredients in Control include menthol, carbomer, cetyl alcohol, dimethicone, fragrance, glyceryl stearate, Laureth-4, Phenoxyethanol, purified water, stearic acid and triethanolamine, as well as butylene glycol, capryl glycol, chamomilla Recutita, flower extract, citrus Aurantium duclis peel oil, cocos Nucifera oil, eucalyptus globulus leaf oil and salvia officinalis extract.
In order to relieve or prevent a cramp, users can apply as much as needed to the area of the affected muscles and massage it onto the skin. Control can also be used safely with compression wraps or compression clothing with the concentration employed in its formula, the company said.
NCPA supports Senate bill empowering FTC action against PBMs
The National Community Pharmacists Association is strongly supporting the Pharmacy Benefit Manager Transparency Act, new legislation introduced today by Sens. Maria Cantwell (D-Wash.) and Chuck Grassley (R-Iowa).
The bill would give the Federal Trade Commission and state attorneys general the ability to penalize and/or initiate legal action against PBMs for certain unfair or deceptive business practices in the commercial space.
“PBM-insurers have manipulated our complex healthcare system, so they can set their competitors’ prices, dictate their competitors’ reimbursements, use competitors’ data to steer patients to PBM-affiliated retail, specialty and mail-order pharmacies, and limit where and what consumers can buy,” said NCPA CEO Douglas Hoey.
“There are plenty of PBM actions for policymakers and regulators to address in order to ease the havoc they have wreaked on patients and small business independent pharmacies,” Hoey said. “NCPA is grateful to Sens. Cantwell and Grassley for their ongoing support of PBM reform. We’re proud to endorse their latest effort, the Pharmacy Benefit Manager Transparency Act, and will work to help it advance.”
Cantwell is chair of the U.S. Senate Commerce Committee. Its subcommittee on Consumer Protection, Product Safety, and Data Security recently had a hearing that examined steps Congress can take to increase transparency in drug prices, require PBMs to operate fairly and ensure the FTC has the authority it needs to stop unfair practices in the prescription drug market. The Pharmacy Benefit Manager Transparency Act, which falls under the Commerce Committee’s jurisdiction, is a natural next step forward in the legislative process. Grassley, like Cantwell, has worked for years to bring more transparency into health care, limit anticompetitive PBM practices and benefit Americans through greater oversight, NCPA said.
SkinnyDipped rolls out strawberry lemonade almonds
SkinnyDipped is debuting its new refreshingly tangy, limited-edition flavor.
Strawberry lemonade almonds are thin-dipped in lightly sweetened yogurt and kissed with real lemon and berry, the Seattle-based company said.
Made without the use of artificial ingredients, the almonds are gluten free, non-GMO, kosher and contain almonds sourced from certified bee-friendly farms.
In addition to launching this new variety, SkinnyDipped is releasing a Beach, Don’t Kill My Vibe bundle, which includes strawberry lemonade and lemon bliss almonds, a tote bag, and branded stickers.
“Strawberry lemonade is the perfect extension for us since we’re all about creating amazingly delicious flavors that are both familiar and unique,” said Breezy Griffith, SkinnyDipped’s CEO and founder. “It’s an even more summery and nostalgic riff on lemon bliss, which people go crazy for! We’re already seeing a ton of excitement and can't wait for more people to try it.”
Consumers can find the strawberry lemonade almonds in a 3.5-oz. pouch that retails for $4.99 at such locations as HelloFresh, Kroger, H-E-B and Hungryroot. The Beach Don’t Kill My Vibe bundle retails for $14.99 at Amazon.
With its latest product, Meno, O Positiv is looking to help alleviate common symptoms of menopause.
Meno is an all-natural and hormone-free capsule formulated with such ingredients as black cohosh, ashwagandha, chaste berry, vitamin D3 and vitamin B6, the company said.
“Following a hysterectomy, menopause hit me like a ton of bricks,” said co-founder Mary Kay. “I was desperate to find a natural, hormone-free menopause solution, but there was nothing available. The effective, premium ingredients in Meno have truly helped me feel like myself again. It's possible to be unaffected by menopause symptoms, live your life and feel great — that’s the reason why we created Meno!”
Designed to help combat hot flashes, night sweats, occasional sleepiness and mood swings, Meno also may aid in improving sexual function, promoting calcium absorption and immunity support, the brand said.
Available in a bottle that contains 30 servings, O Positiv’s Meno retails for $34.99 online.
The Food and Drug Administration has given Amphastar the green light for regadenoson injection 0.08 mg/ml, 5 ml single-dose pre-filled syringe.
Regadenoson, indicated for radionu lide myocardial perfusion imaging in patients unable to undergo adequate exercise stress, is the generic of Astellas Pharma’s Lexiscan.
“We are excited with the FDA's approval of our Regadenoson injection as this broadens our portfolio of products, highlighting our capabilities in combination product development, while providing patients and healthcare providers with another important option. Both the finished product and active pharmaceutical ingredient will be manufactured in the United States," said Jack Zhang, Amphastar's CEO and president.
Lexiscan had a market value of approximately $650 million for the 12 months that ended March 31, 2022, according to IQVIA.
The timing of the commercialization of Amphastar's regadenoson product is subject to the confidential settlement terms agreed to between the company and Astellas.
Hikma announced that Siggi Olafsson has resigned as CEO, as well as from its board of directors, to pursue other opportunities.
Said Darwazah, Hikma’s executive chairman and former CEO, will assume all CEO responsibilities. Olafsson will remain available to the group until he departs on June 24, 2022.
Darwazah will continue to work closely with the executive committee, including Hikma’s three divisional presidents.
Hikma’s board has initiated the process to identify a new CEO.
“On behalf of Hikma’s board and the entire group, I would like to thank Siggi for his leadership over the past four years. Together with the executive committee, he has worked tirelessly to drive strategic momentum across all three businesses, especially during the challenging days of the pandemic. Hikma is on a strong footing and well positioned for future growth, and we wish Siggi well for the future,” Darwazah said.
“It has been a privilege to work for Hikma, and I am proud of what the entire team has achieved during my tenure. I would like to thank the board for their confidence in me throughout the past four years. I would also like to thank my colleagues around the world for their exceptional hard work and commitment,” Olafsson said. “I believe that Hikma has an exciting future and I look forward to seeing the business go from strength to strength.”